ProCE Banner Activity

PARP Inhibitors for Advanced Prostate Cancer: Global Opportunities and Challenges

Clinical Thought

Expert commentary on opportunities and ongoing challenges related to the clinical use of PARP inhibitors for patients with advanced prostate cancer.

Released: July 11, 2024

Expiration: July 10, 2025

Share

Faculty

Karim Fizazi

Karim Fizazi, MD, PhD

Full Professor
Cancer Medicine
Gustave Roussy
Villejuif, France

Joaquin Mateo

Joaquin Mateo, MD, PhD

Medical Oncology Department
Vall d’Hebron University Hospital
Group Leader
Vall d’Hebron Institute of Oncology
Barcelona, Spain

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Pfizer Inc.

Pfizer Inc.

Faculty Disclosure

Primary Author

Karim Fizazi, MD, PhD

Full Professor
Cancer Medicine
Gustave Roussy
Villejuif, France

Karim Fizazi, MD, PhD: consultant/advisor/speaker (paid to institution): Amgen, Astellas, AstraZeneca, Bayer, Clovis, Janssen, MacroGenics, Merck Sharp & Dohme, Novartis/Advanced Accelerator Applications, Pfizer, Sanofi; consultant/advisor/speaker: Arvinas, CureVac, Daiichi Sankyo, Orion.

Joaquin Mateo, MD, PhD

Medical Oncology Department
Vall d’Hebron University Hospital
Group Leader
Vall d’Hebron Institute of Oncology
Barcelona, Spain

Joaquin Mateo, MD, PhD: consultant/advisor/speaker: Amgen, Amunix/Sanofi, AstraZeneca, Guardant Health, Nuage Therapeutics, Pfizer Oncology, Roche.